PE20212327A1 - Ciertos compuestos de pladienolida y metodos de uso - Google Patents
Ciertos compuestos de pladienolida y metodos de usoInfo
- Publication number
- PE20212327A1 PE20212327A1 PE2020001558A PE2020001558A PE20212327A1 PE 20212327 A1 PE20212327 A1 PE 20212327A1 PE 2020001558 A PE2020001558 A PE 2020001558A PE 2020001558 A PE2020001558 A PE 2020001558A PE 20212327 A1 PE20212327 A1 PE 20212327A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl groups
- compounds
- compound
- groups
- oxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Referido a un compuesto de formula I, donde: n se elige entre 0, 1, 2 o 3; R1 se elige entre grupos alquilo C1-C6, grupos cicloalquilo C3-C8, entre otros; uno cualquiera de R2 o R3 se elige entre H y grupos alquilo C1-C6, y el otro se elige entre H, -OR10, -OC(O)R10, -OC(O)R1, y grupos alquilo C1-C6; R4 se elige entre H e hidroxi; R5 y R6 se eligen cada uno independientemente entre grupos alquilo C1-C6; R7 y R8 se eligen cada uno independientemente entre H, hidroxi, grupos alcoxi C1-C6, y grupos alquilo C1-C6; y Y se elige entre fenilo, tiofenilo, triazolilo, entre otros; y sales farmaceuticamente aceptables de los mismos. Un compuesto elegido entre: 4-metilpiperazin-1-carboxilato de [(2S,3S,4E,6S,7S,10S)-7,10-dihidroxi-3,7-dimetil-2-[(2E,4E,6S)-6-metil-9-oxo-9-pirrolidin-1-ilnona-2,4-dien-2-il]-12-oxo-1-oxaciclododec-4-en-6-ilo]. Este compuesto de pladienolida inhibe la expresion genica promovida por VEGF. Tambien se refiere a proceso de sintesis de dichos compuestos, composiciones farmaceuticas que contienen dichos compuestos y su uso en el tratamiento de cancer tales como sindrome mielodisplasico, leucemia linfocitica cronica.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862655021P | 2018-04-09 | 2018-04-09 | |
US201862679653P | 2018-06-01 | 2018-06-01 | |
US201962814843P | 2019-03-06 | 2019-03-06 | |
US201962814838P | 2019-03-06 | 2019-03-06 | |
PCT/US2019/026313 WO2019199667A2 (en) | 2018-04-09 | 2019-04-08 | Certain pladienolide compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20212327A1 true PE20212327A1 (es) | 2021-12-14 |
Family
ID=66248768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020001558A PE20212327A1 (es) | 2018-04-09 | 2019-04-08 | Ciertos compuestos de pladienolida y metodos de uso |
Country Status (18)
Country | Link |
---|---|
US (1) | US11926619B2 (es) |
EP (1) | EP3774759A2 (es) |
JP (2) | JP7335265B2 (es) |
KR (1) | KR20210006907A (es) |
CN (1) | CN113166091A (es) |
AU (2) | AU2019251096B2 (es) |
BR (1) | BR112020020792A2 (es) |
CA (1) | CA3096400A1 (es) |
CL (3) | CL2020002604A1 (es) |
CO (1) | CO2020013834A2 (es) |
IL (3) | IL277749B2 (es) |
JO (2) | JOP20200242A1 (es) |
MX (3) | MX2020010606A (es) |
PE (1) | PE20212327A1 (es) |
PH (1) | PH12020500666A1 (es) |
SG (1) | SG11202009906TA (es) |
TW (1) | TW201945351A (es) |
WO (1) | WO2019199667A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022098712A1 (en) | 2020-11-04 | 2022-05-12 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
CN115414351B (zh) * | 2022-09-19 | 2024-05-17 | 山东大学齐鲁医院 | pladienolide B与PD-L1抗体组合在肿瘤免疫治疗领域的应用 |
WO2024101298A1 (ja) * | 2022-11-07 | 2024-05-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | マクロライド化合物の製造方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
CA2235226A1 (en) | 1995-11-10 | 1997-05-15 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
TWI312681B (en) * | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
AU2003252299A1 (en) | 2002-07-31 | 2004-02-16 | Eisai Co., Ltd. | Novel physiologically active substance |
BR0313039A (pt) | 2002-07-31 | 2005-08-09 | Mercian Corp | Composto, medicamento, composição farmacêutica, método para prevenir ou tratar uma doença contra a qual um controle da expressão do gene é eficaz, método para prevenir ou tratar uma doença contra a qual a supressão da produção de vegf é eficaz, método para prevenir ou tratar uma doença contra a qual uma inibição da angiogênese é eficaz, uso do composto, método para produzir um composto 9-desoxi 1107, linhagem streptomyces sp. a-1543 (ferm bp-8442), método de produzir um composto 6- desoxi, e linhagem a-1544 (ferm bp-8446) ou linhagem a-1545 (ferm bp-8447) |
AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
KR20050086873A (ko) | 2002-11-29 | 2005-08-30 | 메루샹가부시키가이샤 | 매크로라이드계 화합물의 제조 방법 |
EP1705247A4 (en) | 2003-11-27 | 2008-08-20 | Mercian Corp | DNA ACCOMPANYING HYDROXYLATION OF A MAKROLIDE COMPOUND |
US20080280288A1 (en) * | 2004-02-06 | 2008-11-13 | Toshimitsu Uenaka | Assay Method to Predict Sensitivity of Cancer Cell to Anticancer Drug |
WO2006009276A1 (ja) | 2004-07-20 | 2006-01-26 | Eisai R & D Management Co., Ltd. | プラジエノライドの生合成に関与するポリペプチドをコードするdna |
WO2007110705A2 (en) | 2005-09-28 | 2007-10-04 | Novimmune Sa | Macrolide as inhibitors of mhc class ii |
WO2007110704A2 (en) | 2005-09-28 | 2007-10-04 | Novimmune Sa | Macrolide compositions as therapeutic agent |
JPWO2007043621A1 (ja) | 2005-10-13 | 2009-04-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドb及びプラジエノライドdの全合成方法 |
WO2008020584A1 (fr) | 2006-08-14 | 2008-02-21 | Eisai R & D Management Co., Ltd. | Préparation lyophilisée stable |
JPWO2008093853A1 (ja) | 2007-01-29 | 2010-05-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | マクロライド系化合物の固体およびその製造法並びにその医薬組成物 |
US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
CN101730693A (zh) * | 2007-07-06 | 2010-06-09 | 卫材R&D管理有限公司 | 大环内酯系化合物的制造方法及其制造中间体 |
WO2013148324A1 (en) | 2012-03-26 | 2013-10-03 | The Regents Of The University Of California | Anti-cancer polyketide compounds |
BR122022015975B1 (pt) | 2012-05-15 | 2024-01-02 | Bristol-Myers Squibb Company | Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo |
US20140275010A1 (en) | 2013-03-12 | 2014-09-18 | Guo Zhu Zheng | Quaternary salts |
TWI634115B (zh) * | 2014-05-15 | 2018-09-01 | Eisai R&D Management Co., Ltd. | 普拉二烯內酯吡啶化合物及其使用方法 |
US20160009805A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
EP3910073B1 (en) | 2015-09-01 | 2024-03-06 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
KR20180083376A (ko) * | 2015-11-18 | 2018-07-20 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 플라디에놀리드 피리딘 화합물의 고체 상태 형태 및 사용 방법 |
US11998544B2 (en) | 2018-06-01 | 2024-06-04 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
-
2019
- 2019-04-08 SG SG11202009906TA patent/SG11202009906TA/en unknown
- 2019-04-08 EP EP19719036.6A patent/EP3774759A2/en active Pending
- 2019-04-08 JO JOP/2020/0242A patent/JOP20200242A1/ar unknown
- 2019-04-08 BR BR112020020792-6A patent/BR112020020792A2/pt unknown
- 2019-04-08 CN CN201980039253.0A patent/CN113166091A/zh active Pending
- 2019-04-08 WO PCT/US2019/026313 patent/WO2019199667A2/en unknown
- 2019-04-08 JP JP2020555130A patent/JP7335265B2/ja active Active
- 2019-04-08 KR KR1020207032258A patent/KR20210006907A/ko not_active Application Discontinuation
- 2019-04-08 US US17/045,952 patent/US11926619B2/en active Active
- 2019-04-08 IL IL277749A patent/IL277749B2/en unknown
- 2019-04-08 MX MX2020010606A patent/MX2020010606A/es unknown
- 2019-04-08 TW TW108112206A patent/TW201945351A/zh unknown
- 2019-04-08 JO JOP/2020/0243A patent/JOP20200243A1/ar unknown
- 2019-04-08 CA CA3096400A patent/CA3096400A1/en active Pending
- 2019-04-08 IL IL303335A patent/IL303335A/en unknown
- 2019-04-08 PE PE2020001558A patent/PE20212327A1/es unknown
- 2019-04-08 AU AU2019251096A patent/AU2019251096B2/en active Active
-
2020
- 2020-10-08 PH PH12020500666A patent/PH12020500666A1/en unknown
- 2020-10-08 MX MX2023009976A patent/MX2023009976A/es unknown
- 2020-10-08 MX MX2022015216A patent/MX2022015216A/es unknown
- 2020-10-08 CL CL2020002604A patent/CL2020002604A1/es unknown
- 2020-11-05 CO CONC2020/0013834A patent/CO2020013834A2/es unknown
-
2022
- 2022-02-24 CL CL2022000458A patent/CL2022000458A1/es unknown
-
2023
- 2023-04-18 AU AU2023202358A patent/AU2023202358A1/en active Pending
- 2023-08-17 JP JP2023132865A patent/JP2023156456A/ja active Pending
- 2023-08-29 CL CL2023002549A patent/CL2023002549A1/es unknown
-
2024
- 2024-05-09 IL IL312725A patent/IL312725A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US11926619B2 (en) | 2024-03-12 |
JP2021521124A (ja) | 2021-08-26 |
CA3096400A1 (en) | 2019-10-17 |
MX2022015216A (es) | 2023-01-04 |
JOP20200242A1 (ar) | 2020-09-29 |
CL2022000458A1 (es) | 2022-10-21 |
CL2020002604A1 (es) | 2021-01-15 |
IL277749A (en) | 2020-11-30 |
CO2020013834A2 (es) | 2020-12-10 |
SG11202009906TA (en) | 2020-11-27 |
IL303335A (en) | 2023-07-01 |
AU2019251096A1 (en) | 2020-11-26 |
EP3774759A2 (en) | 2021-02-17 |
CN113166091A (zh) | 2021-07-23 |
AU2023202358A1 (en) | 2023-05-18 |
MX2023009976A (es) | 2023-10-30 |
IL277749B2 (en) | 2023-11-01 |
US20210163456A1 (en) | 2021-06-03 |
IL277749B1 (en) | 2023-07-01 |
WO2019199667A2 (en) | 2019-10-17 |
TW201945351A (zh) | 2019-12-01 |
PH12020500666A1 (en) | 2021-07-26 |
IL312725A (en) | 2024-07-01 |
KR20210006907A (ko) | 2021-01-19 |
MX2020010606A (es) | 2021-01-15 |
JP7335265B2 (ja) | 2023-08-29 |
BR112020020792A2 (pt) | 2021-01-12 |
AU2019251096B2 (en) | 2023-04-20 |
JP2023156456A (ja) | 2023-10-24 |
JOP20200243A1 (ar) | 2020-09-29 |
WO2019199667A3 (en) | 2019-11-21 |
CL2023002549A1 (es) | 2024-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20212327A1 (es) | Ciertos compuestos de pladienolida y metodos de uso | |
AR120080A1 (es) | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
AR049464A1 (es) | Antagonistas de receptores de acetilcolina muscarinicos. composiciones farmaceuticas | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
AR071717A1 (es) | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. | |
DOP2010000022A (es) | Derivados de pirimidina 934 | |
AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
AR109735A1 (es) | Método para la síntesis de derivado de 3-fenil-2,3,4,8,9,10-hexahidropirano[2,3-f]cromeno e isómero óptico del mismo | |
AR091490A1 (es) | Antagonistas de iap | |
AR075531A1 (es) | Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros | |
AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
AR101479A1 (es) | Derivados de 6-alquinil-piridina | |
AR101528A1 (es) | Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina | |
AR041883A1 (es) | Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
AR069306A1 (es) | Derivados de metil- bencimidazol como moduladores de receptor x de farnesoide(fxr) | |
CO2020016080A2 (es) | Compuestos | |
AR072880A1 (es) | Derivados nitrogenados de la pancratistatina |